Effects of colesevelam HCl, Avandia (rosiglitazone maleate), or Januvia (sitagliptin) on glycaemic parameters and lipid profiles in subjects with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

Trial Profile

Effects of colesevelam HCl, Avandia (rosiglitazone maleate), or Januvia (sitagliptin) on glycaemic parameters and lipid profiles in subjects with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Colesevelam; Rosiglitazone; Sitagliptin
  • Indications Hyperlipidaemia; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 15 May 2009 Results were presented in a DaiichiSankyo media release, and at the 18th Annual Meeting of the American Association of Clinical Endocrinologists.
    • 10 Apr 2009 Status changed from active, no longer recruiting to completed as reported by clintrial.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top